Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) EBIT (2023 - 2025)

Immunocore Holdings (IMCR) has disclosed EBIT for 3 consecutive years, with -$19.7 million as the latest value for Q4 2025.

  • Quarterly EBIT fell 1.23% to -$19.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$45.4 million through Dec 2025, up 35.63% year-over-year, with the annual reading at -$45.4 million for FY2025, 35.63% up from the prior year.
  • EBIT hit -$19.7 million in Q4 2025 for Immunocore Holdings, down from -$7.2 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$3.6 million in Q1 2025 to a low of -$26.5 million in Q1 2024.
  • Historically, EBIT has averaged -$14.6 million across 3 years, with a median of -$14.8 million in 2023.
  • Biggest five-year swings in EBIT: plummeted 80.25% in 2024 and later skyrocketed 86.35% in 2025.
  • Year by year, EBIT stood at -$17.1 million in 2023, then dropped by 14.07% to -$19.5 million in 2024, then dropped by 1.23% to -$19.7 million in 2025.
  • Business Quant data shows EBIT for IMCR at -$19.7 million in Q4 2025, -$7.2 million in Q3 2025, and -$14.9 million in Q2 2025.